Quarterly report pursuant to Section 13 or 15(d)

Condensed Consolidating Financial Statements - Additional Information (Details)

v3.23.3
Condensed Consolidating Financial Statements - Additional Information (Details)
Jan. 21, 2020
USD ($)
Debtinstrument
Sep. 30, 2023
USD ($)
Sep. 08, 2020
USD ($)
Nov. 06, 2019
Iterum Therapeutics Bermuda Limited        
Condensed Financial Statements Captions [Line Items]        
Ownership percentage       100.00%
Subsidiary Guarantors        
Condensed Financial Statements Captions [Line Items]        
Ownership percentage 100.00%      
2025 Exchangeable Notes        
Condensed Financial Statements Captions [Line Items]        
Aggregate principal amount   $ 12,607,000    
Private Placement | 2025 Exchangeable Notes        
Condensed Financial Statements Captions [Line Items]        
Aggregate principal amount $ 51,588,000      
Debt instrument price per unit 1,000      
Private Placement | RLNs        
Condensed Financial Statements Captions [Line Items]        
Aggregate principal amount $ 103,000      
Number of debt instruments within each notes | Debtinstrument 50      
Rights Offering | 2025 Exchangeable Notes        
Condensed Financial Statements Captions [Line Items]        
Aggregate principal amount     $ 220,000  
Rights Offering | RLNs        
Condensed Financial Statements Captions [Line Items]        
Aggregate principal amount     $ 440